"Fas Ligand Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.
| Descriptor ID |
D053222
|
| MeSH Number(s) |
D12.644.276.374.750.249 D12.776.395.550.312 D12.776.467.374.750.249 D12.776.543.550.312 D23.529.374.750.249
|
| Concept/Terms |
Fas Ligand Protein- Fas Ligand Protein
- CD95L
- Fas Ligand (FasL)
- FasL Protein
- TNF Superfamily, Member 6
- CD178 Antigen
- Antigen, CD178
- Antigens, CD178
- Fas Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 6
- CD178 Antigens
- CD95 Antigen Ligand
- CD95 Ligand
|
Below are MeSH descriptors whose meaning is more general than "Fas Ligand Protein".
Below are MeSH descriptors whose meaning is more specific than "Fas Ligand Protein".
This graph shows the total number of publications written about "Fas Ligand Protein" by people in this website by year, and whether "Fas Ligand Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 3 | 1 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fas Ligand Protein" by people in Profiles.
-
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest. 2019 02 25; 129(4):1551-1565.
-
Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. Hepatology. 2016 07; 64(1):138-50.
-
Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 2015 Jul 22; 5:12463.
-
Exposure to diethylstilbestrol during pregnancy modulates microRNA expression profile in mothers and fetuses reflecting oncogenic and immunological changes. Mol Pharmacol. 2015 May; 87(5):842-54.
-
Plasmacytoid dendritic cells mediate synergistic effects of HIV and lipopolysaccharide on CD27+ IgD- memory B cell apoptosis. J Virol. 2014 Oct; 88(19):11430-41.
-
Prenatal exposure to TCDD triggers significant modulation of microRNA expression profile in the thymus that affects consequent gene expression. PLoS One. 2012; 7(9):e45054.
-
Prenatal exposure of mice to diethylstilbestrol disrupts T-cell differentiation by regulating Fas/Fas ligand expression through estrogen receptor element and nuclear factor-?B motifs. J Pharmacol Exp Ther. 2012 Nov; 343(2):351-61.
-
Oxidative processing of latent Fas in the endoplasmic reticulum controls the strength of apoptosis. Mol Cell Biol. 2012 Sep; 32(17):3464-78.
-
Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck. 2012 Nov; 34(11):1628-33.
-
Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-?B. Mol Nutr Food Res. 2011 Aug; 55(8):1207-18.